Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature

Joyce, Daniel; Sharma, Vidit; Joyce, Daniel D

doi:10.1007/s40273-023-01273-8

Cited by 8 publications

(3 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, there is a significant impetus to develop novel therapies and delivery of existing therapies to decrease recurrence, progression, and need for radical therapy in the NMIBC population. Additionally, bladder cancer is one of the costliest malignancies in the healthcare system [8]. With the high recurrence rates and strict surveillance schedules, NMIBC contributes significantly to the economic burden of healthcare in the United States [9].…”

Section: Introductionmentioning

confidence: 99%

Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review

McNall,

Hooper,

Sullivan

et al. 2024

Cancers

View full text Add to dashboard Cite

The landscape of treatment for non-muscle invasive bladder cancer is rapidly changing. A complete and careful transurethral resection is the mainstay of initial treatment and is followed by intravesical therapy in intermediate or high-risk cases. The standard of care is intravesical BCG. Many alternative or additive approaches to this are being explored. We divided this review into three relevant spaces to consider these novel treatment approaches: (1) low-risk disease, for which intravesical therapy is not usually considered, (2) BCG-naïve disease (i.e., considering alternatives to the standard therapy), and (3) BCG-unresponsive disease. We performed a review of published literature and summarized ongoing trials in the United States. Novel approaches that we explored include surgical techniques for resection, alterations in dwell time for intravesical therapy, delivery method and schedule of intravesical therapies, new intravesical therapy agents, and systemic therapies (especially immunotherapy). These are thoroughly outlined throughout this review article, and the numerous modalities being studied demonstrate significant promise for the future treatment of the expanding space of NMIBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review

McNall,

Hooper,

Sullivan

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Divergent histopathological and behavioral profiles separate non-muscle invasive (NMI, about 70% of total) from muscleinvasive (MI, about 30% of total) tumors [2]. Importantly, UBC represents a remarkable economic impact in health care systems [4], mostly due to the frequent recurrences and stage progression of NMI tumors and the resistance to standard-of-care cisplatin-based therapy of patients portending MI disease [2]. In this latter group, the prognosis is aggravated by comorbidities and frailty typical of the elderly population, with the median overall survival being approximately 15 months for metastatic UBC patients [5].…”

Section: Introductionmentioning

confidence: 99%

Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect

Afonso,

Barbosa-Matos,

Silvestre

et al. 2024

Cancers

View full text Add to dashboard Cite

Advanced urothelial bladder cancer (UBC) patients are tagged by a dismal prognosis and high mortality rates, mostly due to their poor response to standard-of-care platinum-based therapy. Mediators of chemoresistance are not fully elucidated. This work aimed to study the metabolic profile of advanced UBC, in the context of cisplatin resistance. Three isogenic pairs of parental cell lines (T24, HT1376 and KU1919) and the matching cisplatin-resistant (R) sublines were used. A set of functional assays was used to perform a metabolic screening on the cells. In comparison to the parental sublines, a tendency was observed towards an exacerbated glycolytic metabolism in the cisplatin-resistant T24 and HT1376 cells; this glycolytic phenotype was particularly evident for the HT1376/HT1376R pair, for which the cisplatin resistance ratio was higher. HT1376R cells showed decreased basal respiration and oxygen consumption associated with ATP production; in accordance, the extracellular acidification rate was also higher in the resistant subline. Glycolytic rate assay confirmed that these cells presented higher basal glycolysis, with an increase in proton efflux. While the results of real-time metabolomics seem to substantiate the manifestation of the Warburg phenotype in HT1376R cells, a shift towards distinct metabolic pathways involving lactate uptake, lipid biosynthesis and glutamate metabolism occurred with time. On the other hand, KU1919R cells seem to engage in a metabolic rewiring, recovering their preference for oxidative phosphorylation. In conclusion, cisplatin-resistant UBC cells seem to display deep metabolic alterations surpassing the Warburg effect, which likely depend on the molecular signature of each cell line.

show abstract

“…Non-muscle invasive bladder cancer (NMIBC) is characterized by frequent recurrences and patients require life-long monitoring, making it one of the more expensive cancers to manage [1]. There are few biomarkers that have been confirmed to be predictive of patient response to therapy.…”

Section: Introductionmentioning

confidence: 99%

The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact Therapy

Patwardhan,

Mahendran

2023

IJMS

View full text Add to dashboard Cite

The tumor microenvironment (TME) is complex and involves many different cell types that seemingly work together in helping cancer cells evade immune monitoring and survive therapy. The advent of single-cell sequencing has greatly increased our knowledge of the cell types present in the tumor microenvironment and their role in the developing cancer. This, coupled with clinical data showing that cancer development and the response to therapy may be influenced by drugs that indirectly influence the tumor environment, highlights the need to better understand how the cells present in the TME work together. This review looks at the different cell types (cancer cells, cancer stem cells, endothelial cells, pericytes, adipose cells, cancer-associated fibroblasts, and neuronal cells) in the bladder tumor microenvironment. Their impact on immune activation and on shaping the microenvironment are discussed as well as the effects of hypertensive drugs and anesthetics on bladder cancer.

show abstract

Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature

Cited by 8 publications

References 82 publications

Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review

Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review

Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect

The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact Therapy

Contact Info

Product

Resources

About